AR and neoplasm: Eligible men include those with diagnosed mCRPC that had progressed after both a next-generation androgen-receptor pathway inhibitor and a taxane, who harbored germline or somatic BRCA1/2 alterations, confirmed by testing of tumor tissue or plasma sequencing (in this case, ctDNA) in a central reference laboratory, or through a validated local assay.